Immediate Placebo Effect in Parkinson’s Disease – Is the Subjective Relief Accompanied by Objective Improvement?

Background: A recent well-conducted meta-analysis showed that placebo effect is associated with a possible small benefit for subjective outcomes, but has no significant effects on objective outcomes. Objective: Herein, we aimed to investigate the immediate effects of two different types of placebo [placebo pill and sham transcranial magnetic stimulation (TMS)] in Parkinson’s disease (PD) patients and compared them to the standard treatment (levodopa) in a proper randomized, double-blind, crossover clinical trial. Methods: PD patients received three different interventions on different days: levodopa, placebo pill, and sham TMS. The motor function was assessed using simple and choice reaction time, Unified Parkinson’s Disease Rating Scale (UPDRS), finger tapping, Purdue Pegboard test, time to button up, walking time and supination-pronation. The subjective motor function was measured by a visual analogue scale (VAS). Results: The results showed that there was a significant motor function in the motor function only after the treatment with levodopa, but not after treatment with placebo pills or sham TMS. However, patients reported a similar subjective improvement in motor function indexed by VAS following these three treatments. Conclusion: These results suggest that placebo interventions in PD may have an immediate subjective sensation of improvement but result in no significant objective motor changes compared with levodopa treatment. Although physiological changes are possible after a placebo intervention, our findings suggest that the acute placebo effect in PD may be the result of the subjective change in the motor rating only.

[1]  R A Deyo,et al.  The importance of placebo effects in pain treatment and research. , 1994, JAMA.

[2]  J Valls-Solé,et al.  Akinesia in Parkinson's disease. I. Shortening of simple reaction time with focal, single‐pulse transcranial magnetic stimulation , 1994, Neurology.

[3]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[4]  McDonald Cj Is the placebo powerless , 2001 .

[5]  S. Leurgans,et al.  Objective changes in motor function during placebo treatment in PD , 2000, Neurology.

[6]  M Schulzer,et al.  Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease , 2001, Science.

[7]  福永 幹彦 Hrobjartsson A, Gotzsche PC : Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment , 2002 .

[8]  A. Hrõbjartsson,et al.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. , 2001, The New England journal of medicine.

[9]  H. Przuntek,et al.  Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson's disease. , 2004, Journal of neural transmission. Supplementum.

[10]  Dylan Evans Suppression of the acute-phase response as a biological mechanism for the placebo effect. , 2005, Medical hypotheses.

[11]  E. Wassermann Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. , 1998, Electroencephalography and clinical neurophysiology.

[12]  A. Destée,et al.  Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease , 2000, European Neurology.

[13]  F. Benedetti,et al.  Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/Nocebo Responses , 2003, The Journal of Neuroscience.

[14]  C. Sylvén,et al.  "Improvement" in the placebo group could be due to regression to the mean as well as to sociobiologic factors. , 2006, The American journal of cardiology.

[15]  R. Lilford,et al.  Is the placebo powerless? , 2001, The New England journal of medicine.

[16]  C J McDonald,et al.  How much of the placebo 'effect' is really statistical regression? , 1983, Statistics in medicine.

[17]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[18]  Ji Hyun Ko,et al.  Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: The contribution of expectation , 2006, NeuroImage.

[19]  Donald D. Price,et al.  Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms , 2005, Pain.

[20]  Á. Pascual-Leone,et al.  Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  D. Spiegel Mind matters -- group therapy and survival in breast cancer. , 2001, The New England journal of medicine.

[22]  H. Spiro Doctors, patients, and placebos , 1986 .

[23]  S. Leurgans,et al.  Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[24]  H. Przuntek,et al.  Choice reaction time after levodopa challenge in parkinsonian patients , 2000, Journal of the Neurological Sciences.

[25]  D. Vaillancourt,et al.  Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. , 2004, Brain : a journal of neurology.